ProQR Therapeutics NV reports results for the quarter ended in March - Earnings Summary

ProQR Therapeutics NV

16/05/2023 12:59

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly
adjusted
loss of 11 cents​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 11 cents per share.
    * Revenue fell 46.9% to €655.00 thousand from a year ago;
analysts
expected €1.32 million. 
    * ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 11 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * ProQR Therapeutics NV shares had fallen by 9.9% this
quarter and
lost 48.1% so far this year.
    * The company reported a quarterly loss of €8.93 million.
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
16 at 11:59 a.m. UTC. ​All figures in euros unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.11          -0.11          Met
 Dec. 31 2022      -0.16          -0.16          Met
 Sep. 30 2022      -0.21          -0.34          Missed
 Jun. 30 2022      -0.22          -0.21          Beat